IL250622B2 - Prepared sirp-alpha fusion proteins and pharmaceutical preparations containing them - Google Patents

Prepared sirp-alpha fusion proteins and pharmaceutical preparations containing them

Info

Publication number
IL250622B2
IL250622B2 IL250622A IL25062217A IL250622B2 IL 250622 B2 IL250622 B2 IL 250622B2 IL 250622 A IL250622 A IL 250622A IL 25062217 A IL25062217 A IL 25062217A IL 250622 B2 IL250622 B2 IL 250622B2
Authority
IL
Israel
Prior art keywords
seq
sirpa
egfr
huigg1
sirpav2
Prior art date
Application number
IL250622A
Other languages
English (en)
Hebrew (he)
Other versions
IL250622A0 (en
IL250622B (en
Inventor
Kin-Ming Lo
Nora Zizlsperger
Aroop Sircar
Original Assignee
Merck Patent Gmbh
Lo Kin Ming
Nora Zizlsperger
Aroop Sircar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53872055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL250622(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh, Lo Kin Ming, Nora Zizlsperger, Aroop Sircar filed Critical Merck Patent Gmbh
Publication of IL250622A0 publication Critical patent/IL250622A0/en
Publication of IL250622B publication Critical patent/IL250622B/en
Publication of IL250622B2 publication Critical patent/IL250622B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL250622A 2014-08-15 2017-02-15 Prepared sirp-alpha fusion proteins and pharmaceutical preparations containing them IL250622B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462038196P 2014-08-15 2014-08-15
PCT/EP2015/068798 WO2016024021A1 (en) 2014-08-15 2015-08-14 Sirp-alpha immunoglobulin fusion proteins

Publications (3)

Publication Number Publication Date
IL250622A0 IL250622A0 (en) 2017-04-30
IL250622B IL250622B (en) 2022-12-01
IL250622B2 true IL250622B2 (en) 2023-04-01

Family

ID=53872055

Family Applications (1)

Application Number Title Priority Date Filing Date
IL250622A IL250622B2 (en) 2014-08-15 2017-02-15 Prepared sirp-alpha fusion proteins and pharmaceutical preparations containing them

Country Status (22)

Country Link
US (1) US11021694B2 (enExample)
EP (2) EP3180363B2 (enExample)
JP (1) JP6764858B2 (enExample)
KR (1) KR20170036796A (enExample)
CN (1) CN107108748A (enExample)
AU (1) AU2015303135B2 (enExample)
BR (1) BR112017002646A2 (enExample)
CA (1) CA2956126A1 (enExample)
DK (1) DK3180363T3 (enExample)
ES (1) ES2751915T5 (enExample)
HR (1) HRP20191872T1 (enExample)
HU (1) HUE046661T2 (enExample)
IL (1) IL250622B2 (enExample)
LT (1) LT3180363T (enExample)
MX (1) MX377196B (enExample)
PL (1) PL3180363T3 (enExample)
PT (1) PT3180363T (enExample)
RU (1) RU2017108203A (enExample)
SG (1) SG11201701189TA (enExample)
SI (1) SI3180363T1 (enExample)
WO (1) WO2016024021A1 (enExample)
ZA (1) ZA201701810B (enExample)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20192013T1 (hr) 2012-12-17 2020-02-07 Trillium Therapeutics Inc. Liječenje cd47+ oboljelih stanica sa sirp alfa-fc fuzijama
WO2014144357A1 (en) * 2013-03-15 2014-09-18 Merck Patent Gmbh Tetravalent bispecific antibodies
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
EP3105246B1 (en) 2014-02-10 2021-03-31 Merck Patent GmbH Targeted tgf beta inhibition
DK3180363T3 (da) 2014-08-15 2019-11-04 Merck Patent Gmbh Sirp-alpha-immunoglobulin fusionsproteiner
CN107531805A (zh) * 2015-03-05 2018-01-02 弗雷德哈钦森癌症研究中心 免疫调节融合蛋白及其用途
WO2017027422A1 (en) 2015-08-07 2017-02-16 Alexo Therapeutics Inc. Constructs having a sirp-alpha domain or variant thereof
BR112018006578A2 (pt) 2015-10-01 2018-12-26 Heat Biologics, Inc. composições e métodos para juntar domínios extracelulares tipo i e tipo ii como proteínas quiméricas heterólogas
CN107149682B (zh) * 2016-03-04 2022-01-04 复旦大学 一种靶向cd47的免疫检查点抑制剂药物组合物及其制备方法
WO2017184553A1 (en) * 2016-04-18 2017-10-26 Baylor College Of Medicine Cancer gene therapy targeting cd47
US11560433B2 (en) 2016-05-27 2023-01-24 Albert Einstein College Of Medicine Methods of treatment by targeting VCAM1 and MAEA
CN107459578B (zh) * 2016-05-31 2021-11-26 泰州迈博太科药业有限公司 一种靶向cd47与pd-l1的双功能融合蛋白
WO2018008470A1 (ja) * 2016-07-05 2018-01-11 国立大学法人神戸大学 抗腫瘍剤
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
US11498977B2 (en) 2016-09-29 2022-11-15 Beijing Hanmi Pharmaceutical Co., Ltd. Heterodimeric immunoglobulin constructs and preparation methods thereof
EP3411071A4 (en) 2016-10-20 2019-08-28 I-Mab NOVEL MONOCLONAL CD47 ANTIBODY AND USES THEREOF
CA3042581A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Enhancement of cd47 blockade therapy by proteasome inhibitors
US11779631B2 (en) 2016-11-03 2023-10-10 Pfizer Inc. CD47 blockade therapy by HDAC inhibitors
CN106519036B (zh) * 2016-11-04 2019-06-11 新乡医学院 抗cd47和egfr的双功能蛋白及其制备方法与应用
CA3043652A1 (en) 2016-11-18 2018-05-24 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
CN108220334A (zh) * 2016-12-09 2018-06-29 上海迈泰君奥生物技术有限公司 无血清细胞培养基及高效表达重组蛋白质的方法
WO2018127918A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A sirp alpha-cd70 fusion protein and methods of use thereof
PL3565828T3 (pl) 2017-01-05 2022-04-04 Kahr Medical Ltd. Białko fuzyjne SIRP1 ALFA-41BBL i sposoby jego zastosowania
RU2769513C2 (ru) 2017-01-05 2022-04-01 Кахр Медикал Лтд. Слитый белок pd1-4-1bbl и способы его применения
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
BR112019017713A2 (pt) 2017-02-27 2020-04-07 Shattuck Labs Inc proteínas quiméricas à base de csf1r
CN110290798B (zh) 2017-02-27 2024-04-05 沙塔克实验室有限公司 基于vsig8的嵌合蛋白
CN118994414A (zh) 2017-02-27 2024-11-22 沙塔克实验室有限公司 基于tigit和light的嵌合蛋白
CN108623689B (zh) * 2017-03-15 2020-10-16 宜明昂科生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制备方法和用途
MX2019010812A (es) 2017-03-17 2019-12-11 Hutchinson Fred Cancer Res Proteinas de fusion inmunomoduladoras y sus usos.
US11518810B2 (en) 2017-05-08 2022-12-06 Shanghai Jmt-Bio Technology Co., Ltd. Bispecific recombinant protein and use thereof
CN111448323B (zh) * 2017-06-07 2023-12-01 长源赋能(上海)生命科技有限公司 精确制导的多功能治疗抗体
US11401329B2 (en) 2017-08-02 2022-08-02 Phanes Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
WO2019043059A1 (en) * 2017-08-30 2019-03-07 Symphogen A/S COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER BY ANTI-EGFR ANTIBODIES
US11529425B2 (en) 2017-09-07 2022-12-20 Dingfu Biotarget Co., Ltd. Immunoconjugates comprising signal regulatory protein alpha
KR20190037164A (ko) * 2017-09-28 2019-04-05 한국과학기술연구원 신규 암 치료용 조성물
EP3694890A4 (en) * 2017-10-12 2021-11-03 Immunowake Inc. LIGHT CHAIN ANTIBODY FUSION PROTEIN WITH VEGFR
EP3700938A1 (en) * 2017-10-26 2020-09-02 ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. Novel recombinant fusion proteins, preparation and use thereof
EP3541941A4 (en) * 2017-11-10 2019-12-25 I-Mab Biopharma US Limited FUSION PROTEINS CONTAINING ANTI-CD47 ANTIBODIES AND CYTOKINES
AU2017439776B2 (en) * 2017-11-20 2025-03-27 Taizhou Mabtech Pharmaceutical Co., Ltd Bifunctional fusion protein targeting CD47 and PD-l1
EA202091364A1 (ru) 2017-12-04 2020-10-13 Бейджин Ханми Фармасьютикал Ко., Лтд. Анти-pd-l1/анти-cd47 биспецифическое антитело с подобной природному антителу структурой и в форме гетеродимера и способ его получения
JP6961090B2 (ja) * 2017-12-08 2021-11-05 ハンクス バイオファーマシューティクス，インコーポレイテッド 抗ｐｄ−１／ｃｄ４７二重特異性抗体及びその適用
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
AU2019235627B2 (en) * 2018-03-13 2026-01-15 Pfizer Inc. Improvements in CD47 blockade therapy by EGFR antibody
EP3768314A4 (en) 2018-03-21 2022-01-05 ALX Oncology Inc. ANTIBODIES AGAINST ALPHA SIGNAL REGULATING PROTEIN AND METHODS OF USE
CN110386984B (zh) * 2018-04-17 2022-04-22 杭州尚健生物技术有限公司 结合cd47蛋白的融合蛋白及其应用
CN108794641A (zh) * 2018-07-04 2018-11-13 上海科医联创生物科技有限公司 一种针对EGFRvIII的多功能融合蛋白及其应用
CA3104778A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. Pd1-4-1bbl variant fusion protein and methods of use thereof
KR102945860B1 (ko) * 2018-07-11 2026-03-31 카 메디컬 리미티드 SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
WO2020029982A1 (en) 2018-08-08 2020-02-13 Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd Recombinant bifunctional protein targeting cd47 and her2
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
AU2019336345A1 (en) 2018-09-04 2021-04-15 Pfizer Inc. CD47 blockade with parp inhibition for disease treatment
CN109535258A (zh) * 2018-10-26 2019-03-29 上海科弈药业科技有限公司 一种针对Her2+肿瘤的多功能融合蛋白及其应用
CN113260632A (zh) * 2018-10-29 2021-08-13 蒂嘉特克斯公司 包含IgA抗体构建体的组合物和方法
US12492231B2 (en) 2018-11-14 2025-12-09 Jn Biosciences Llc Multimeric hybrid Fc proteins for replacement of IVIG
CN111303293B (zh) * 2018-11-14 2022-08-30 杭州尚健生物技术有限公司 一种融合蛋白及其用途
BR112021009275A2 (pt) * 2018-11-15 2022-01-04 Byondis Bv Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira.
CN109535263B (zh) * 2018-12-04 2022-06-17 江苏东抗生物医药科技有限公司 SIRPα突变体及其融合蛋白
CN109517054B (zh) * 2018-12-04 2022-04-08 江苏东抗生物医药科技有限公司 SIRPα变体或其融合蛋白及其应用
BR112021012040A2 (pt) * 2018-12-21 2021-11-03 Ose Immunotherapeutics Molécula anti-pd-1/sirpa bifuncional
JP2022523543A (ja) * 2019-03-06 2022-04-25 ジエンス ヘンルイ メデイシンカンパニー リミテッド 二機能性融合タンパク質及びその医薬的使用
CN111763261B (zh) * 2019-04-02 2022-08-09 杭州尚健生物技术有限公司 一种融合蛋白及其用途
TW202104260A (zh) 2019-04-05 2021-02-01 美商西建公司 腫瘤選擇性結合ｃｄ４７之抗體之工程
KR20220044904A (ko) 2019-05-31 2022-04-12 알렉소 온콜로지 인크. 면역 관문 억제제와 병용하는 sirp 알파 fc 융합으로 암을 치료하는 방법
KR20220034117A (ko) * 2019-06-14 2022-03-17 더 스크립스 리서치 인스티튜트 면역 관문 차단 이중특이성 분자
US12358987B2 (en) * 2019-07-08 2025-07-15 Nanjing GenScript Biotech Co., Ltd. Anti-CD47/anti-PD-1 bispecific antibody, preparation method and use thereof
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
WO2021013215A1 (zh) * 2019-07-23 2021-01-28 南京金斯瑞生物科技有限公司 抗cd47/抗lag-3双特异抗体及其制备方法和应用
CN114641308A (zh) * 2019-08-28 2022-06-17 伦敦国王学院 B细胞靶向的平行CAR(pCAR)治疗剂
KR102902719B1 (ko) 2019-10-18 2025-12-24 포티 세븐, 엘엘씨 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료
CA3153636A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
EP4056592A4 (en) * 2019-11-08 2024-03-20 Jiangsu Simcere Pharmaceutical Co., Ltd. ANTIBODY AGAINST HUMAN PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) AND USE THEREOF
CN114845710A (zh) 2019-11-27 2022-08-02 Alx肿瘤生物技术公司 用于治疗癌症的组合疗法
EP4445902A3 (en) 2019-12-24 2024-12-18 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
CN117964757A (zh) 2020-02-14 2024-05-03 吉利德科学公司 与ccr8结合的抗体和融合蛋白及其用途
WO2021191870A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
KR20230033647A (ko) 2020-06-30 2023-03-08 멘두스 비.브이. 난소암 백신에서 백혈병 유래 세포의 용도
CN111808183B (zh) * 2020-07-25 2022-07-08 北京吉尔麦迪生物医药科技有限公司 一种靶向CD47的高亲和力SIRPα突变体及其融合蛋白
US20230365703A1 (en) * 2020-09-17 2023-11-16 Shanghai Lyn-Crest Enterprise Management Co., Ltd. Bispecific recombinant protein and use thereof
JP2023545983A (ja) * 2020-10-07 2023-11-01 セルジーン コーポレイション リンパ系悪性腫瘍状態の二重特異性抗体治療
US20220196651A1 (en) * 2020-12-06 2022-06-23 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
CN112708675A (zh) * 2020-12-25 2021-04-27 中山大学肿瘤防治中心 骨髓nk细胞联合mcl1抑制剂在抗白血病中的应用
CN112656941A (zh) * 2021-01-20 2021-04-16 福建医科大学附属协和医院 抗cd47单克隆抗体在制备抗阿霉素耐药的急性淋巴细胞白血病细胞的药物中应用
WO2022190058A1 (en) 2021-03-12 2022-09-15 Dcprime B.V. Methods of vaccination and use of cd47 blockade
US20240182572A1 (en) * 2021-04-09 2024-06-06 Ose Immunotherapeutics Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
BR112023022774A2 (pt) 2021-05-13 2024-01-02 Alx Oncology Inc Terapias de combinação para tratamento de câncer
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN120329453A (zh) * 2021-07-19 2025-07-18 百奥泰生物制药股份有限公司 基于Luciferase报告基因系统的重组嵌合膜蛋白及其应用
WO2023003331A1 (en) * 2021-07-19 2023-01-26 Yuhan Corporation Sirp-alpha variants and use thereof
CN113956363B (zh) * 2021-10-13 2023-03-31 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和cd24的重组融合蛋白及其制备和用途
WO2023072217A1 (en) * 2021-10-28 2023-05-04 Guangzhou Lintonpharm Co., Ltd. Fusion proteins targeting cd3 and cd47
AU2022375782B2 (en) 2021-10-28 2026-02-26 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
AU2022376954B2 (en) 2021-10-29 2026-04-23 Gilead Sciences, Inc. Cd73 compounds
WO2023079438A1 (en) 2021-11-08 2023-05-11 Pfizer Inc. Enhancement of cd47 blockade therapy with anti-vegf agents
CA3236718A1 (en) * 2021-12-21 2023-06-29 Fbd Biologics Limited Engineered sirp.alpha. variants and methods of use thereof
CA3237577A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2022419982B2 (en) 2021-12-22 2026-04-16 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN118401564A (zh) * 2022-01-18 2024-07-26 Fbd生物制品有限公司 靶向cd47/pd-l1的蛋白质复合物和其使用方法
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
EP4493554A1 (en) 2022-03-17 2025-01-22 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
EP4499837A1 (en) 2022-03-24 2025-02-05 Bitterroot Bio, Inc. Sirp-alpha fusion polypeptides with modified fc domains
US20250257113A1 (en) * 2022-03-24 2025-08-14 The Board Of Trustees Of The Leland Stanford Junior University Multivalent sirp-alpha fusion polypeptides
AU2023239488A1 (en) * 2022-03-25 2024-11-14 WuXi Biologics Ireland Limited Anti-her2/anti-cd47 molecules and uses thereof
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
CR20240451A (es) 2022-04-21 2024-12-04 Gilead Sciences Inc Compuestos de modulación de kras g12d
AU2023263628A1 (en) * 2022-05-06 2024-12-19 Biosion Inc. Recombinant fusion protein targeting cd40 and cd47
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) * 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
PE20250758A1 (es) 2022-07-01 2025-03-13 Gilead Sciences Inc Compuestos de cd73
KR20250036855A (ko) 2022-07-12 2025-03-14 길리애드 사이언시즈, 인코포레이티드 Hiv 면역원성 폴리펩타이드 및 백신, 및 이들의 용도
CN116041470B (zh) * 2022-08-04 2024-10-22 四川大学华西医院 具有高亲和力结合肿瘤细胞cd47的细胞膜材料及其制备方法和应用
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
KR20250075602A (ko) * 2022-09-23 2025-05-28 광저우 린톤팜 컴퍼니 리미티드 분리된 항원 결합 단백질 및 이의 용도
CN120225509A (zh) 2022-12-22 2025-06-27 吉利德科学公司 Prmt5抑制剂及其用途
CN118546255A (zh) * 2023-02-24 2024-08-27 恒翼生物医药(上海)股份有限公司 一种靶向αvβ3和CD47的双功能融合蛋白以及其应用
EP4683654A1 (en) * 2023-03-22 2026-01-28 Li, Wangzhi Sirp variants and uses thereof
AU2024252725A1 (en) 2023-04-11 2025-11-06 Gilead Sciences, Inc. Kras modulating compounds
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
CN119451994A (zh) 2023-05-31 2025-02-14 Fbd生物制品有限公司 靶向cd47/pd-l1的蛋白质复合物和其使用方法
AU2024306338A1 (en) 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
KR20260046403A (ko) 2023-07-26 2026-04-07 길리애드 사이언시즈, 인코포레이티드 Parp7 저해제
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
AU2024337913A1 (en) 2023-09-08 2026-03-26 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025247303A1 (zh) * 2024-05-30 2025-12-04 上海艾乐晞生物科技有限公司 具有pH依赖结合活性的人信号调节蛋白α突变体及其应用
WO2026039365A1 (en) 2024-08-12 2026-02-19 Gilead Sciences, Inc. Kras modulating compounds
WO2026089992A1 (en) 2024-10-21 2026-04-30 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930706D0 (en) 1999-12-24 2000-02-16 Medical Res Council Composition for inhibiting macrophage activity
US20090191202A1 (en) * 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
CA2627446A1 (en) 2005-11-21 2007-05-31 Laboratoires Serono S.A. Compositions and methods of producing hybrid antigen binding molecules and uses thereof
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
EP2573112A1 (en) 2007-10-11 2013-03-27 The Hospital For Sick Children Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
EP2111869A1 (en) † 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
CN102257001A (zh) † 2008-12-19 2011-11-23 诺瓦提斯公司 治疗自体免疫和炎性病症的可溶性多肽
EP4311863A3 (en) * 2009-05-15 2024-04-10 University Health Network Compositions and methods for treating hematologic cancers targeting the sirp alpha- cd47 interaction
US8758750B2 (en) 2009-09-15 2014-06-24 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-CD47 therapy for hematologic cancers
EP4349868A3 (en) 2010-05-14 2024-08-28 The Board of Trustees of the Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
JP6460796B2 (ja) 2012-01-17 2019-01-30 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 高親和性ｓｉｒｐ−アルファ試薬
HRP20192013T1 (hr) 2012-12-17 2020-02-07 Trillium Therapeutics Inc. Liječenje cd47+ oboljelih stanica sa sirp alfa-fc fuzijama
WO2014121093A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
WO2014144357A1 (en) 2013-03-15 2014-09-18 Merck Patent Gmbh Tetravalent bispecific antibodies
CN106459218B (zh) * 2014-03-24 2021-03-02 宜明昂科生物医药技术（上海）有限公司 新的重组双功能融合蛋白、其制剂和用途
ES2962260T3 (es) 2014-08-08 2024-03-18 Univ Leland Stanford Junior Proteínas de fusión SIRPa alfa-anticuerpo
DK3180363T3 (da) 2014-08-15 2019-11-04 Merck Patent Gmbh Sirp-alpha-immunoglobulin fusionsproteiner

Also Published As

Publication number Publication date
LT3180363T (lt) 2019-11-25
ES2751915T5 (es) 2022-12-23
EP3180363B2 (en) 2022-09-14
SG11201701189TA (en) 2017-03-30
DK3180363T3 (da) 2019-11-04
CN107108748A (zh) 2017-08-29
SI3180363T1 (sl) 2020-05-29
ZA201701810B (en) 2020-10-28
US11021694B2 (en) 2021-06-01
KR20170036796A (ko) 2017-04-03
MX2017001712A (es) 2017-04-27
WO2016024021A1 (en) 2016-02-18
EP3180363A1 (en) 2017-06-21
BR112017002646A2 (pt) 2018-02-27
RU2017108203A (ru) 2018-09-17
PT3180363T (pt) 2019-11-05
HRP20191872T1 (hr) 2020-02-07
HUE046661T2 (hu) 2020-03-30
JP2017525698A (ja) 2017-09-07
AU2015303135B2 (en) 2021-05-20
PL3180363T3 (pl) 2020-02-28
EP3643727A1 (en) 2020-04-29
AU2015303135A1 (en) 2017-02-23
ES2751915T3 (es) 2020-04-02
IL250622A0 (en) 2017-04-30
MX377196B (es) 2025-03-07
US20160177276A1 (en) 2016-06-23
JP6764858B2 (ja) 2020-10-07
EP3180363B1 (en) 2019-09-25
CA2956126A1 (en) 2016-02-18
RU2017108203A3 (enExample) 2019-03-13
IL250622B (en) 2022-12-01

Similar Documents

Publication Publication Date Title
EP3180363B2 (en) Sirp-alpha immunoglobulin fusion proteins
US11208459B2 (en) Constructs having a SIRP-alpha domain or variant thereof
JP7611931B2 (ja) ガイダンス及びナビゲーションコントロール（ｇｎｃ）抗体様タンパク質、その製造方法及び使用方法
IL260958B2 (en) Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
IL260920B (en) Constructs of psma and cd3 bispecific antigens that bind to t-cells, preparations containing them and uses thereof
IL319311A (en) Low pH pharmaceutical composition containing T cells involved in antibody constructs
AU2021206543A1 (en) Multispecific antibodies that bind both mait and tumor cells
JP2025061426A (ja) 抗グリピカン３抗体
IL302586A (en) Polypeptide constructs selectively binding to cldn6 and cd3
IL298076A (en) Multispecific antibodies
IL321948A (en) Anti-IL-18 BP antibodies
HK40028997A (en) Sirp-alpha immunoglobulin fusion proteins
HK1237789B (en) Sirp-alpha immunoglobulin fusion proteins
HK1237789A1 (en) Sirp-alpha immunoglobulin fusion proteins
Adams et al. A Tetravalent PD-L1/VEGF Bispecific Antibody Blocks Tumor Growth In Vivo
IL317523A (en) FcRn-binding polypeptides and uses thereof
JP2025539145A (ja) 抗ｃｄ１３７抗体及びその使用方法
IL324231A (en) T cell engager masking molecules